TABLE 3 .
Test and permutated Q2 (quality assessment statistic) scores for OPLS-DA models of 1H HR-MAS spectra of M. smegmatis mc2 155a
| Treatment | Q2 | Q2 (permutated) |
|---|---|---|
| Tyloxapol (0.025%) | 0.866 | −0.377 |
| D-LAK120-A | 0.769 | −0.423 |
| D-LAK120-HP13 | 0.729 | −0.360 |
| Rifampin | 0.581 | −0.426 |
| Rifampin + D-LAK120-A | 0.763 | −0.410 |
| Rifampin + D-LAK120-HP13 | 0.430 | −0.429 |
| Capreomycin | 0.881 | −0.347 |
| Capreomycin + D-LAK120-A | 0.775 | −0.367 |
| Capreomycin + D-LAK120-HP13 | 0.823 | −0.344 |
a
Comparison of test and permutated Q2 scores for cross-validated OPLS-DA models comparing 1H HR-MAS spectra of unchallenged M. smegmatis mc2 155 with those obtained for bacteria under the indicated conditions.